Quantitative analysis of mRNA-1273 COVID-19 vaccination response in immunocompromised adult hematology patients

被引：50

作者：

Haggenburg, Sabine ^{[1
]}

Lissenberg-Witte, Birgit, I ^{[2
]}

van Binnendijk, Rob S. ^{[3
]}

den Hartog, Gerco ^{[3
]}

Bhoekhan, Michel S. ^{[1
]}

Haverkate, Nienke J. E. ^{[4
]}

de Rooij, Dennis M. ^{[4
]}

van Meerloo, Johan ^{[5
]}

Cloos, Jacqueline ^{[5
]}

Kootstra, Neeltje A. ^{[4
]}

Wouters, Dorine ^{[6
]}

Weijers, Suzanne S. ^{[7
]}

van Leeuwen, Ester M. M. ^{[4
,8
]}

Bontkes, Hetty J. ^{[8
]}

Tonouh-Aajoud, Saida ^{[8
]}

Heemskerk, Mirjam H. M. ^{[9
]}

Sanders, Rogier W. ^{[10
]}

Roelandse-Koop, Elianne ^{[6
]}

Hofsink, Quincy ^{[1
]}

Groen, Kazimierz ^{[1
]}

Cetinel, Lucia ^{[1
]}

Schellekens, Louis ^{[1
]}

den Hartog, Yvonne M. ^{[1
]}

Toussaint, Belle ^{[1
]}

Kant, Iris M. J. ^{[1
]}

Graas, Thecla ^{[1
]}

de Pater, Emma ^{[1
]}

Dik, Willem A. ^{[11
]}

Engel, Marije D. ^{[1
]}

Pierie, Cheyenne R. N. ^{[1
]}

Janssen, Suzanne R. ^{[1
]}

van Dijkman, Edith ^{[1
]}

Poniman, Meliawati ^{[10
]}

Burger, Judith A. ^{[10
]}

Bouhuijs, Joey H. ^{[10
]}

Smits, Gaby ^{[3
]}

Rots, Nynke Y. ^{[3
]}

Zweegman, Sonja ^{[1
,5
]}

Kater, Arnon P. ^{[1
,5
]}

van Meerten, Tom ^{[12
]}

Mutsaers, Pim G. N. J. ^{[1
]}

van Doesum, Jaap A. ^{[12
]}

Broers, Annoek E. C. ^{[1
]}

van Gils, Marit J. ^{[10
]}

Goorhuis, Abraham ^{[13
]}

Rutten, Caroline E. ^{[1
]}

Hazenberg, Mette D. ^{[1
,5
,14
]}

Nijhof, Inger S. ^{[1
,5
]}

机构：

[1] Univ Amsterdam, Dept Hematol, Med Ctr, Amsterdam, Netherlands

[2] Univ Amsterdam, Dept Epidemiol & Data Sci, Med Ctr, Amsterdam, Netherlands

[3] Natl Inst Publ Hlth & Environm, Ctr Immunol Infect Dis & Vaccines, Bilthoven, Netherlands

[4] Univ Amsterdam, Dept Expt Immunol, Med Ctr, Amsterdam, Netherlands

[5] Univ Amsterdam, Canc Ctr Amsterdam, Med Ctr, Amsterdam, Netherlands

[6] Univ Amsterdam, Dept Clin Chem, Med Ctr, Amsterdam, Netherlands

[7] Univ Amsterdam, Cent Diagnost Lab, Med Ctr, Amsterdam, Netherlands

[8] Univ Amsterdam, Lab Med Immunol, Med Ctr, Amsterdam, Netherlands

[9] Leiden Univ, Dept Hematol, Med Ctr, Leiden, Netherlands

[10] Univ Amsterdam, Dept Med Microbiol & Infect Prevent, Med Ctr, Amsterdam, Netherlands

[11] Erasmus MC, Dept Immunol, Lab Med Immunol, Univ Med Ctr, Rotterdam, Netherlands

[12] Univ Med Ctr Groningen, Dept Hematol, Groningen, Netherlands

[13] Univ Amsterdam, Dept Infect Dis, Med Ctr, Amsterdam, Netherlands

[14] Sanquin Res, Dept Hematopoiesis, Amsterdam, Netherlands

来源：

BLOOD ADVANCES | 2022年 / 6卷 / 05期

基金：

荷兰研究理事会;

关键词：

IMMUNE-RESPONSES; RECIPIENTS;

D O I：

10.1182/bloodadvances.2021006917

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Vaccination guidelines for patients treated for hematological diseases are typically conservative. Given their high risk for severe COVID-19, it is important to identify those patients that benefit from vaccination. We prospectively quantified serum immunoglobulin G (IgG) antibodies to spike subunit 1 (S1) antigens during and after 2-dosemRNA-1273 (Spikevax/Moderna) vaccination in hematology patients. Obtaining S1 IgG >= 300 binding antibody units (BAUs)/mLwas considered adequate as it represents the lower level of S1 IgG concentration obtained in healthy individuals, and it correlates with potent virus neutralization. Selected patients (n = 723) were severely immunocompromised owing to their disease or treatment thereof. Nevertheless, >= 50% of patients obtained S1 IgG >= 300 BAUs/mL after 2-dosemRNA-1273. All patients with sickle cell disease or chronicmyeloid leukemia obtained adequate antibody concentrations. Around 70% of patients with chronic graft-versus-host disease (cGVHD), multiple myeloma, or untreated chronic lymphocytic leukemia (CLL) obtained S1 IgG >= 300 BAUs/mL. Ruxolitinib or hypomethylating therapy but not high-dose chemotherapy blunted responses inmyeloidmalignancies. Responses in patients with lymphoma, patients with CLL on ibrutinib, and chimeric antigen receptor T-cell recipients were low. The minimal time interval after autologous hematopoietic cell transplantation (HCT) to reach adequate concentrations was <= 2months formultiplemyeloma, 8months for lymphoma, and 4 to 6 months after allogeneic HCT. Serum IgG4, absolute B- and natural killer-cell number, and number of immunosuppressants predicted S1 IgG >= 300 BAUs/mL. Hematology patients on chemotherapy, shortly after HCT, or with cGVHD should not be precluded fromvaccination.

引用

页码：1537 / 1546

页数：10

共 36 条

[1] Suboptimal Response to Coronavirus Disease 2019 Messenger RNA Vaccines in Patients With Hematologic Malignancies: A Need for Vigilance in the Postmasking Era [J].

Agha, Mounzer E. ;

Blake, Maggie ;

Chilleo, Charles ;

Wells, Alan ;

Haidar, Ghady .

OPEN FORUM INFECTIOUS DISEASES, 2021, 8 (07)

[2] Secondary Immunodeficiency in Hematological Malignancies: Focus on Multiple Myeloma and Chronic Lymphocytic Leukemia [J].

Allegra, Alessandro ;

Tonacci, Alessandro ;

Musolino, Caterina ;

Pioggia, Giovanni ;

Gangemi, Sebastiano .

FRONTIERS IN IMMUNOLOGY, 2021, 12

[3] Case Study: Prolonged Infectious SARS-CoV-2 Shedding from an Asymptomatic Immunocompromised Individual with Cancer [J].

Avanzato, Victoria A. ;

Matson, M. Jeremiah ;

Seifert, Stephanie N. ;

Pryce, Rhys ;

Williamson, Brandi N. ;

Anzick, Sarah L. ;

Barbian, Kent ;

Judson, Seth D. ;

Fischer, Elizabeth R. ;

Martens, Craig ;

Bowden, Thomas A. ;

de Wit, Emmie ;

Riedo, Francis X. ;

Munster, Vincent J. .

CELL, 2020, 183 (07) :1901-+

[4] Transmissibility and viral replication of SARS-COV-2 in immunocompromised patients [J].

Beran, Azizullah ;

Zink, Evan ;

Mhanna, Mohammed ;

Abugharbyeh, Aya ;

Hanrahan, Jennifer ;

Duggan, Joan ;

Assaly, Ragheb .

JOURNAL OF MEDICAL VIROLOGY, 2021, 93 (07) :4156-4160

[5] Comparison of the clinical course of COVID-19 infection in sickle cell disease patients with healthcare professionals [J].

Boga, Can ;

Asma, Suheyl ;

Leblebisatan, Goksel ;

Sen, Nazan ;

Tombak, Anil ;

Demiroglu, Yusuf Ziya ;

Yeral, Mahmut ;

Akin, Sule ;

Yesilagac, Hasan ;

Habesoglu, Mehmet Ali ;

Aribogan, Anis ;

Kasar, Mutlu ;

Korur, Asli ;

Ozdogu, Hakan .

ANNALS OF HEMATOLOGY, 2021, 100 (09) :2195-2202

[6]

Caniels TG, 2021, SCI ADV, V7, DOI [10.1101/2021.05.26.21257441, 10.1126/sciadv.abj5365]

[7] Vaccination of haemopoietic stem cell transplant recipients: guidelines of the 2017 European Conference on Infections in Leukaemia (ECIL 7) [J].

Cordonnier, Catherine ;

Einarsdottir, Sigrun ;

Cesaro, Simone ;

Di Blasi, Roberta ;

Mikulska, Malgorzata ;

Rieger, Christina ;

de Lavallade, Hugues ;

Gallo, Giuseppe ;

Lehrnbecher, Thomas ;

Engelhard, Dan ;

Ljungman, Per ;

Akova, Murat ;

Aljurf, Mahmoud ;

Averbuch, Diana ;

Bergeron, Anne ;

Blijlevens, Nicole ;

de Sousa, Aida Botelho ;

Busca, Alessandro ;

Calandra, Thierry ;

Cesaro, Simone ;

Crocchiolo, Roberto ;

De Greef, Julien ;

de la Camara, Rafael ;

Donnelly, Peter ;

Drgona, Lubos ;

Duarte, Rafael ;

Einarsdottir, Sigrun ;

Einsele, Hermann ;

Greinix, Hildegard ;

Herbrecht, Raoul ;

Hill, Joshua ;

Hubacek, Petr ;

Kassa, Csaba ;

Klyasova, Galina ;

Koltan, Sylwia ;

Lortholary, Olivier ;

Lundgren, Jens ;

Maertens, Johan ;

Martino, Rodrigo ;

Maschmeyer, Georg ;

Mellinghoff, Sibylle ;

Navarro, David ;

Nosari, Anna Maria ;

Pagano, Livio ;

Paukssen, Karlis ;

Penack, Olaf ;

Racil, Zdenek ;

Robin, Christine ;

Roilides, Emmanuel ;

Rovira, Montserrat .

LANCET INFECTIOUS DISEASES, 2019, 19 (06) :E200-E212

[8] Tyrosine kinase inhibitors impair B-cell immune responses in CML through off-target inhibition of kinases important for cell signaling [J].

de Lavallade, Hugues ;

Khoder, Ahmad ;

Hart, Melanie ;

Sarvaria, Anushruti ;

Sekine, Takuya ;

Alsuliman, Abdullah ;

Mielke, Stephan ;

Bazeos, Alexandra ;

Stringaris, Kate ;

Ali, Sara ;

Milojkovic, Dragana ;

Foroni, Letizia ;

Chaidos, Aristeidis ;

Cooper, Nichola ;

Gabriel, Ian ;

Apperley, Jane ;

Belsey, Sarah ;

Flanagan, Robert J. ;

Goldman, John ;

Shpall, Elizabeth J. ;

Kelleher, Peter ;

Marin, David ;

Rezvani, Katayoun .

BLOOD, 2013, 122 (02) :227-238

[9] Persistence of Antibodies to Severe Acute Respiratory Syndrome Coronavirus 2 in Relation to Symptoms in a Nationwide Prospective Study [J].

den Hartog, Gerco ;

Vos, Eric R. A. ;

van den Hoogen, Lotus L. ;

van Boven, Michiel ;

Schepp, Rutger M. ;

Smits, Gaby ;

van Vliet, Jeffrey ;

Woudstra, Linde ;

Wijmenga-Monsuur, Alienke J. ;

van Hagen, Cheyenne C. E. ;

Sanders, Elisabeth A. M. ;

de Melker, Hester E. ;

van der Klis, Fiona R. M. ;

van Binnendijk, Robert S. .

CLINICAL INFECTIOUS DISEASES, 2021, 73 (12) :2155-2162

[10] SARS-CoV-2 Specific Antibody Detection for Seroepidemiology: A Multiplex Analysis Approach Accounting for Accurate Seroprevalence [J].

den Hartog, Gerco ;

Schepp, Rutger M. ;

Kuijer, Marjan ;

GeurtsvanKessel, Corine ;

van Beek, Josine ;

Rots, Nynke ;

Koopmans, Marion P. G. ;

van der Klis, Fiona R. M. ;

van Binnendijk, Robert S. .

JOURNAL OF INFECTIOUS DISEASES, 2020, 222 (09) :1452-1461

← 1 2 3 4 →